Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 20 of 57 for “"Pemetrexed"”.

  1. Active efflux transport and CNS distribution of the novel antifolate pemetrexed.

    Pemetrexed (PMX, Alimta®) is a novel multi-targeted antifolate approved for the treatment of malignant pleural mesothelioma and non-small cell lung cancer (NSCLC). Given the high incidence of brain metastasis in NSCLC patients and wide use of the classic antifolate, methotrexate (MTX), in primary …

    umn Repository record for Active efflux transport and CNS distribution of the novel antifolate pemetrexed. (opens in a new tab)

  2. Schedule-dependent interactions between pemetrexed and vinorelbine in human lung cancer cells

    … was to investigate the interactions between pemetrexed and vinorelbine for human adenocarcinoma via various chemotherapy schedules. Vinorelbine and pemetrexed caused a strong dose-dependent cytotoxic effect in both HCC and cisplatin resistant HCC (HCC-res) cells. The IC50 values of …

    lmu-germany Repository record for Schedule-dependent interactions between pemetrexed and vinorelbine in human lung cancer cells (opens in a new tab)

  3. Sorafenib enhances pemetrexed-induced cytotoxicity through and autophagy-dependent mechanism in cancer cells

    … pathways known to regulate cell survival. Pemetrexed, an FDA-approved anti-folate drug, targets thymidylate synthase (TS) and a secondary folate-dependent enzyme, 5’ aminoimidazole-carboximide ribonucleotide formyltransferase (AICART); both important for DNA synthesis. Studies performed by …

    vcu Repository record for Sorafenib enhances pemetrexed-induced cytotoxicity through and autophagy-dependent mechanism in cancer cells (opens in a new tab)

  4. Pemetrexed in primary central nervous system lymphoma: a phase-I dose finding study

    … and tolerability of a novel anti-folate drug, pemetrexed, in the setting of a phase I clinical trial in patients with non-HIV related central nervous system lymphoma (CNSL). METHODS: In this multicenter, open-label, phase I dose finding clinical trial, pemetrexed was investigated as a single …

    bu Repository record for Pemetrexed in primary central nervous system lymphoma: a phase-I dose finding study (opens in a new tab)

  5. Pemetrexed, A Modulator of AMP-activated Kinase Signaling and an Inhibitor of Wild type and Mutant p53

    … mesothelioma, leukemia, and breast cancers. When pemetrexed (PTX) was discovered, our laboratory had established that the primary mechanism of action of pemetrexed is to inhibit thymidylate 22 synthase (TS) (E. Taylor et al., 1992). Preclinical studies have shown that PTX has a broad range of …

    vcu Repository record for Pemetrexed, A Modulator of AMP-activated Kinase Signaling and an Inhibitor of Wild type and Mutant p53 (opens in a new tab)

  6. Discovery and Development of Predictive Biomarkers for the Personalization of Pemetrexed Therapy in Non-Small Cell Lung Cancer

    … rates to the FDA-approved chemotherapeutic pemetrexed. To do so, clinically-applicable response phenotypes of a large panel of lung cancer lines needed to be defined to identify gene expression profiles driving response to pemetrexed treatment. To mimic clinical exposure and duration in …

    utswmed Repository record for Discovery and Development of Predictive Biomarkers for the Personalization of Pemetrexed Therapy in Non-Small Cell Lung Cancer (opens in a new tab)

  7. ANTIFOLATE MODULATORS OF AMP-ACTIVATED PROTEIN KINASE SIGNALING AS CANCER THERAPEUTICS

    … it was appreciated that the antifolate pemetrexed had multiple targets within folate metabolism. This laboratory was instrumental in showing that pemetrexed elicited its primary action as a thymidylate synthase inhibitor. Unusual for an antifolate, pemetrexed showed significant clinical …

    vcu Repository record for ANTIFOLATE MODULATORS OF AMP-ACTIVATED PROTEIN KINASE SIGNALING AS CANCER THERAPEUTICS (opens in a new tab)

  8. RHEB DYNAMICS ON LYSOSOMAL MEMBRANES DETERMINES MTORC1 ACTIVITY AFTER LOSS OF P53 OR ACTIVATION OF AMPK

    … PTEN, LKB1, and Akt. The antifolate pemetrexed was found by this laboratory to activate AMPK via the inhibition of the enzyme AICART in de novo purine synthesis. This work presents a mechanism of mTORC1 activation with p53 loss, as well as of mTORC1 inhibition by pemetrexed-induced …

    vcu Repository record for RHEB DYNAMICS ON LYSOSOMAL MEMBRANES DETERMINES MTORC1 ACTIVITY AFTER LOSS OF P53 OR ACTIVATION OF AMPK (opens in a new tab)

  9. Crystal Structures of Binary and Ternary Complexes of Thymidylate Synthase (ThyA) from Mycobacterium tuberculosis: Insights into Selectivity and Inhibition

    … inhibitor, shown to have a Ki of 2nM for Mtb TS. Pemetrexed and Raltitrexed are both anti-folates, targeting the cofactor binding site of thymidylate synthase. The x-ray crystal structures of Mycobacterium tuberculosis thymidylate synthase were solved in the binary complexes ThyA-dUMP and …

    tamu Repository record for Crystal Structures of Binary and Ternary Complexes of Thymidylate Synthase (ThyA) from Mycobacterium tuberculosis: Insights into Selectivity and Inhibition (opens in a new tab)

  10. Αναδρομική καταγραφή χημειοθεραπείας δεύτερης γραμμής σε ασθενείς με μεσοθηλίωμα

    ΠΕΡΙΛΗΨΗ Ο συνδυασμός πλατίνας-pemetrexed αποτελεί τον χρυσό κανόνα στην χημειοθεραπεία πρώτης γραμμής ασθενών με μεσοθηλίωμα. Η συχνή όμως υποτροπή, κάνει την επιλογή χημειοθεραπείας δεύτερης γραμμής κρίσιμη για αυτούς. Στην πτυχιακή αυτή εργασία μελετήθηκαν αναδρομικά 98 ασθενείς με κακόηθες …

    athens Repository record for Αναδρομική καταγραφή χημειοθεραπείας δεύτερης γραμμής σε ασθενείς με μεσοθηλίωμα (opens in a new tab)

  11. AN ECONOMIC ANALYSIS OF THE ADDITION OF BEVACIZUMAB TO STANDARD CHEMOTHERAPY IN PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA

    … III trial, MAPS (Mesothelioma Avastin Cisplatin Pemetrexed Study), investigated the addition of bevacizumab to cisplatin plus pemetrexed (PCB) as compared to pemetrexed plus cisplatin (PC) alone in malignant pleural mesothelioma (MPM) patients. The trial results indicate that patients taking …

    washington Repository record for AN ECONOMIC ANALYSIS OF THE ADDITION OF BEVACIZUMAB TO STANDARD CHEMOTHERAPY IN PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA (opens in a new tab)

  12. THERAPEUTIC EFFICACY OF COMBINATION OF MTOR INHIBITORS AND AMPK ACTIVATORS IN NON-SMALL CELL LUNG CANCER.

    Pemetrexed (PTX), an antifolate drug, has been approved by the US FDA for first line therapy of mesothelioma and non-small cell lung cancer. In addition to its primary site of action on thymidylate synthase (TS), PTX also inhibits the second folate-dependent enzyme of purine biosynthesis …

    vcu Repository record for THERAPEUTIC EFFICACY OF COMBINATION OF MTOR INHIBITORS AND AMPK ACTIVATORS IN NON-SMALL CELL LUNG CANCER. (opens in a new tab)

  13. Personalized Pharmacological Approaches as the Cornerstone of Modern Lung Cancer Therapy

    … biomarkers for immunotherapy, and the use of pemetrexed in patients with impaired kidney function. Our research shows that interactions between SMIs and blood thinners (DOACs) often require dose adjustments or alternatives to prevent bleeding or thrombosis. Additionally, we found that the …

    radboud Repository record for Personalized Pharmacological Approaches as the Cornerstone of Modern Lung Cancer Therapy (opens in a new tab) Download PDF for Personalized Pharmacological Approaches as the Cornerstone of Modern Lung Cancer Therapy (opens in a new tab)

  14. Synthesis and Characterization of Polymeric Nanoparticle Structures for Control Drug Delivery in Cancer Therapies and Temperature Effects on Drug Release

    … characteristics. The encapsulation of the drug pemetrexed was improved by using polyethileneimine. The high positive charge density of polyethileneimine causes a strong electrostatic interaction with the carboxylic acids of pemetrexed; this complex decreases the solubility of pemetrexed and …

    arizona-thes Repository record for Synthesis and Characterization of Polymeric Nanoparticle Structures for Control Drug Delivery in Cancer Therapies and Temperature Effects on Drug Release (opens in a new tab)

  15. Opportunities in optimizing cytotoxic treatment of lung cancer in the era of immunotherapy

    … and personalize the dosing of carboplatin, pemetrexed, docetaxel, and atezolizumab in the treatment of advanced non-small cell lung cancer (NSCLC) patients.. For carboplatin, it is recommended to adopt cystatin C-based estimation of drug clearance. This approach incorporates patient-specific …

    radboud Repository record for Opportunities in optimizing cytotoxic treatment of lung cancer in the era of immunotherapy (opens in a new tab) Download PDF for Opportunities in optimizing cytotoxic treatment of lung cancer in the era of immunotherapy (opens in a new tab)

  16. Mechanism and Functional Consequence of MRP2 Mislocalization in Nonalcoholic Steatohepatitis

    … of Mrp2 transport capacity was completed using pemetrexed, a novel Mrp2 probe substrate. Comparison of biliary excretion of pemetrexed between wild-type and Mrp2^(-/-) rats shows a 100% decrease, confirming that it relies upon Mrp2 for biliary excretion. NASH rats exhibited a 60% decrease in …

    arizona-thes Repository record for Mechanism and Functional Consequence of MRP2 Mislocalization in Nonalcoholic Steatohepatitis (opens in a new tab)

Page 1 of 3